A Phase 3 interventional study of Personalized Exercise Program in Non Small Cell Lung Cancer and Secondary Lung Cancer, sponsored by University of Utah. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by University of Utah · Phase 3, Interventional, and Treatment
Among 10 studies in Carcinoma, Non-Small-Cell Lung by University of Utah — 2 open to participants now, 3 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · University of Utah.
Among the 10 studies in Carcinoma, Non-Small-Cell Lung by University of Utah, this one is the only one that started in 2017, is the only one in phase 3, and was the 5th registered.
7,620 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 10 studies in Carcinoma, Non-Small-Cell Lung by University of Utah are open now, in 1 country. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+
University of Utah · Sites in United States
By country, each count listing its studies:
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 986 (74%) set no upper age limit and 226 (17%) stop at 75 or younger; 34 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 2 · Phase 3 1
First in 2006; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 182 is above the median of 62 across 6,019 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 24 across the 9 interventional studies, 144,400 across the 1 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Utah is the lead sponsor of 994 studies on the registry; 175 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.
2 of the studies in Carcinoma, Non-Small-Cell Lung by University of Utah that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06945484University of UtahPILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study | 2027-01 |
| NCT06934343University of UtahMachine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data | 2027-08-31 |
Among the 10 studies in Carcinoma, Non-Small-Cell Lung by University of Utah, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3 study aimed at investigating the effects of a personalized exercise program (PEP) in NSCLC patients (stage I, II, IIIa) and secondary lung cancer patients undergoing surgical treatment at the University of Utah and comparing the intervention to the current standard of care (no exercise program).
This is a Phase 3 study aimed at investigating the effects of a personalized exercise program (PEP) in NSCLC patients (stage I, II, IIIa) and secondary lung cancer patients undergoing surgical treatment at the University of Utah and comparing the intervention to the current standard of care (no exercise program).
Eligible patients will be randomized between two arms (1:1 ratio) prior to the surgery and will be followed for approximately 6 months post-surgery:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Behavioral: Personalized Exercise Program
The PEP intervention involves a combination of home-based exercise as well as in-patient exercise. The exercise modes will include basic transfer and calisthenics mobility, aerobic and resistance exercises and will be performed in various postures (supine, sitting, standing and walking) with variable challenges (level walking, bending, inclines, steps and squatting). For patients randomized to the Intervention Group (Group 1), the PEP intervention will be personalized, implemented, and modified (based on the patients AM-PAC mobility stage) by a licensed physical therapist in face-to-face, virtual, or phone meetings (\~30-40 minutes). An exercise education manual, specifically developed for this study, will be used by the physical therapist to educate the patients on all aspects of starting and maintaining the exercise intervention.
Mobility Performance - Six Minute Walk (6MW) Distance
Six Minute Walk (6MW) distance is the distance patients can walk indoors on a 25-meter level, smooth-surfaced track over the course of 6 minutes. This outcome will report the mean 6MW distance at hospital discharge (up to 38 days after the initiation of the study intervention), at the 2-Month Post Surgery Visit (up to 5 months from the initiation of the study intervention), and at the 6-Month Post Surgery Visit (up to 9 months from the initiation of the study intervention).
Time frame: Hospital Discharge (up to 38 days after the initiation of the study therapy), 2-Month Post Surgery Visit (up to 5 months after the initiation of the study therapy), and 6-Month Post Surgery Visit (up to 9 months after the initiation of study therapy)
Evaluate the Change Short Physical Performance Battery (SPPB) Score
This outcome will report the results from the Short Physical Performance Battery (SPPB). This secondary outcome measure is associated with the evaluation of improvement in physical performance is the result of the short physical performance battery test. The SPPB score (ranging from 0 to 12) will be obtained for each patient at the time points described above. A score of 0 indicates the worst performance, and a score of 12 indicates the best performance. This outcome will report median SPPB scores at hospital discharge (up to 38 days after the initiation of the study intervention), at the 2-Month Post Surgery Visit (up to 5 months from the initiation of the study intervention), and at the 6-Month Post Surgery Visit (up to 9 months from the initiation of the study intervention).
Time frame: Hospital Discharge (up to 38 days after the initiation of the study therapy), 2-Month Post Surgery Visit (up to 5 months after the initiation of the study therapy), and 6-Month Post Surgery Visit (up to 9 months after the initiation of study therapy)
FACT-L (Functional Assessment of Cancer Therapy-Lung) Questionnaire
The FACT-L (Functional Assessment of Cancer Therapy-Lung) questionnaire assesses health-related quality of life (QOL). Total scores range from 0-136, with lower scores representing worse QOL and higher scores representing better QOL. This outcome measure will report mean FACT-L total scores at Hospital Discharge (up to 38 days after the initiation of the study therapy), 2-Month Post Surgery Visit (up to 5 months after the initiation of the study therapy), and 6-Month Post Surgery Visit (up to 9 months after the initiation of the study therapy).
Time frame: Hospital Discharge (up to 38 days after the initiation of the study therapy), 2-Month Post Surgery Visit (up to 5 months after the initiation of the study therapy), and 6-Month Post Surgery Visit (up to 9 months after the initiation of the study therapy)
Fatigue Subscale (FS)
This outcome will report the results of the Fatigue Subscale (FS) from the FACIT-F (Chronic Illness Fatigue Scale) questionnaire. The FACIT-F is a self-reported evaluation of fatigue in cancer patients. This questionnaire has patients rank statements regarding physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns from 0 Not at All to 4 Very Much. This outcome will report the FS score from the FACIT-F. The FS has a minimum of 0 and a maximum of 52; the higher the score the better the Quality of Life (QOL). The FS Score is calculated from 13 survey items. Individual items that were "reverse items" (meaning a high value indicates poor QOL) were subtracted from 4. Then all "reverse items" and normal items were added together to calculate the FS score. This assessment was scored according to the FACIT-F Scoring Guidelines (Version 4).
Time frame: Hospital Discharge (up to 38 days after the initiation of the study therapy), 2-Month Post Surgery Visit (up to 5 months after the initiation of the study therapy), and 6-Month Post Surgery Visit (up to 9 months after the initiation of study therapy)
BREQ-3 (Behavioral Regulation in Exercise Questionnaire 3) Questionnaire
This outcome will report the results of the BREQ-3. The questionnaire has 24 items, each item ranging from 0 "Not True for Me" to 4 "Very True for Me". This questionnaire will report 6 sub-scores, Amotivation, External Regulation, Introjected Regulation, Identified Regulation, Integrated Regulation, Intrinsic Regulation. Each sub score is a the average of 4 items, ranging from 0-4 with higher values indicating higher motivation.
Time frame: Hospital Discharge (up to 38 days after the initiation of the study therapy), 2-Month Post Surgery Visit (up to 5 months after the initiation of the study therapy), and 6-Month Post Surgery Visit (up to 9 months after the initiation of study therapy)
| Milestone | Personalized Exercise Program | Standard of Care - No Exercise |
|---|---|---|
| Started | 92 | 90 |
| Completed | 82 | 85 |
| Not completed | 10 | 5 |
| Withdrew: Withdrawal by subject | 7 | 2 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Did not perform 6mw test | 3 | 2 |
| Milestone | Personalized Exercise Program | Standard of Care - No Exercise |
|---|---|---|
| Started | 82 | 85 |
| Completed | 82 | 82 |
| Not completed | 0 | 3 |
| Withdrew: Death | 0 | 3 |
Six Minute Walk (6MW) distance is the distance patients can walk indoors on a 25-meter level, smooth-surfaced track over the course of 6 minutes. This outcome will report the mean 6MW distance at hospital discharge (up to 38 days after the initiation of the study intervention), at the 2-Month Post Surgery Visit (up to 5 months from the initiation of the study intervention), and at the 6-Month Post Surgery Visit (up to 9 months from the initiation of the study intervention).
| meters | Personalized Exercise Program | Standard of Care - No Exercise |
|---|---|---|
| Hospital Discharge | 409.8 ± 169.8 | 411.0 ± 164.3 |
| 2-Month Post Surgery Visit | 490.5 ± 127.6 | 475.9 ± 129.5 |
| 6-Month Post Surgery Visit | 483.1 ± 151.9 | 463.3 ± 180 |
This outcome will report the results from the Short Physical Performance Battery (SPPB). This secondary outcome measure is associated with the evaluation of improvement in physical performance is the result of the short physical performance battery test. The SPPB score (ranging from 0 to 12) will be obtained for each patient at the time points described above. A score of 0 indicates the worst performance, and a score of 12 indicates the best performance. This outcome will report median SPPB scores at hospital discharge (up to 38 days after the initiation of the study intervention), at the 2-Month Post Surgery Visit (up to 5 months from the initiation of the study intervention), and at the 6-Month Post Surgery Visit (up to 9 months from the initiation of the study intervention).
| score on a scale | Personalized Exercise Program | Standard of Care - No Exercise |
|---|---|---|
| Hospital Discharge | 11 (9 to 12) | 11.5 (8.5 to 12) |
| 2-Month Post Surgery Visit | 12 (11 to 12) | 12 (10 to 12) |
| 6-Month Post Surgery Visit | 12 (11 to 12) | 12 (11 to 12) |
The FACT-L (Functional Assessment of Cancer Therapy-Lung) questionnaire assesses health-related quality of life (QOL). Total scores range from 0-136, with lower scores representing worse QOL and higher scores representing better QOL. This outcome measure will report mean FACT-L total scores at Hospital Discharge (up to 38 days after the initiation of the study therapy), 2-Month Post Surgery Visit (up to 5 months after the initiation of the study therapy), and 6-Month Post Surgery Visit (up to 9 months after the initiation of the study therapy).
| score on a scale | Personalized Exercise Program | Standard of Care - No Exercise |
|---|---|---|
| Hospital Discharge | 100 ± 18.1 | 101.5 ± 17.0 |
| 2-Month Follow up | 106.4 ± 14.8 | 103.5 ± 17.1 |
| 6-Month Follow up | 106.5 ± 16 | 105.9 ± 15.7 |
This outcome will report the results of the Fatigue Subscale (FS) from the FACIT-F (Chronic Illness Fatigue Scale) questionnaire. The FACIT-F is a self-reported evaluation of fatigue in cancer patients. This questionnaire has patients rank statements regarding physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns from 0 Not at All to 4 Very Much. This outcome will report the FS score from the FACIT-F. The FS has a minimum of 0 and a maximum of 52; the higher the score the better the Quality of Life (QOL). The FS Score is calculated from 13 survey items. Individual items that were "reverse items" (meaning a high value indicates poor QOL) were subtracted from 4. Then all "reverse items" and normal items were added together to calculate the FS score. This assessment was scored according to the FACIT-F Scoring Guidelines (Version 4).
| score on a scale | Personalized Exercise Program | Standard of Care - No Exercise |
|---|---|---|
| Hospital Discharge | 34.5 ± 11.4 | 33.5 ± 12.1 |
| 2 Month Follow-up Visit | 38.6 ± 8.7 | 36 ± 10.7 |
| 6-Month Follow-up | 38.2 ± 10.2 | 37.5 ± 11.3 |
This outcome will report the results of the BREQ-3. The questionnaire has 24 items, each item ranging from 0 "Not True for Me" to 4 "Very True for Me". This questionnaire will report 6 sub-scores, Amotivation, External Regulation, Introjected Regulation, Identified Regulation, Integrated Regulation, Intrinsic Regulation. Each sub score is a the average of 4 items, ranging from 0-4 with higher values indicating higher motivation.
| score on a scale | Personalized Exercise Program | Standard of Care - No Exercise |
|---|---|---|
| Discharge: Amotivation | 0.2 ± 0.5 | 0.2 ± 0.5 |
| Discharge: External Regulation | 0.8 ± 1.1 | 0.9 ± 1.0 |
| Discharge: Introjected Regulation | 1.7 ± 1.1 | 1.7 ± 1 |
| Discharge: Identified Regulation | 2.9 ± .8 | 2.8 ± 0.9 |
| Discharge: Integrated Regulation | 2.2 ± 1.3 | 2.1 ± 1.2 |
| Discharge: Intrinsic Regulation | 2.3 ± 1.2 | 2.3 ± 1.2 |
| 2-Month: Amotivation | 0.1 ± 0.3 | 0.2 ± 0.4 |
| 2-Month: External Regulation | 0.8 ± 1 | 0.90 ± 1 |
| 2-Months: Introjected Regulation | 1.7 ± 1.1 | 1.7 ± 1.1 |
| 2-Months: Identified Regulation | 3.0 ± 0.7 | 2.9 ± 0.9 |
| 2-Months: Integrated Regulation | 2.2 ± 1.1 | 2.1 ± 1.2 |
| 2-Months: Intrinsic Regulation | 2.2 ± 1 | 2.3 ± 1.1 |
| 6-Months: Amotivation | 0.2 ± 0.4 | 0.3 ± 0.6 |
| 6-Months: External Regulation | 0.8 ± 1.0 | 0.8 ± 1.0 |
| 6-Months: Introjected Regulation | 1.9 ± 1.1 | 1.8 ± 1.2 |
| 6-Months: Identified Regulation | 3.1 ± 0.8 | 2.9 ± 0.9 |
| 6-Months: Integrated Regulation | 2.4 ± 1.2 | 2.3 ± 1.1 |
| 6-Months: Intrinsic Regulation | 2.4 ± 1.1 | 2.4 ± 1.2 |
Collected over Adverse event, Safety Adverse Event, and All Cause Mortality data were collected from the initiation of the study intervention to the Month 6 Follow-Up Visit, up to 6 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Personalized Exercise Program | 0/92 (0%) | 0/92 (0%) | 5/92 (5.4%) |
| Standard of Care - No Exercise | 4/90 (4.4%) | 0/90 (0%) | 0/90 (0%) |
| Event | Personalized Exercise Program | Standard of Care - No Exercise |
|---|---|---|
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/92 | 0/90 |
| Muscle weakness lower limbMusculoskeletal and connective tissue disorders | 1/92 | 0/90 |
| Joint range of motion decreased cervical spineMusculoskeletal and connective tissue disorders | 1/92 | 0/90 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/92 | 0/90 |
| Joint range of motion decreasedMusculoskeletal and connective tissue disorders | 1/92 | 0/90 |
| Age, Continuous(years) | Personalized Exercise Program | Standard of Care - No Exercise | Total |
|---|---|---|---|
| Mean | 62.7 ± 14.7 | 62.7 ± 13.0 | 62.7 ± 13.8 |
| Sex: Female, Male(Participants) | Personalized Exercise Program | Standard of Care - No Exercise | Total |
|---|---|---|---|
| Female | 51 | 57 | 108 |
| Male | 41 | 33 | 74 |
| Ethnicity (NIH/OMB)(Participants) | Personalized Exercise Program | Standard of Care - No Exercise | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 6 | 10 |
| Not Hispanic or Latino | 86 | 83 | 169 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Personalized Exercise Program | Standard of Care - No Exercise | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 86 | 83 | 169 |
| More than one race | 1 | 2 | 3 |
| Unknown or Not Reported | 3 | 4 | 7 |
| Region of Enrollment(participants) | Personalized Exercise Program | Standard of Care - No Exercise | Total |
|---|---|---|---|
| United States | 92 | 90 | 182 |
| Rural-Urban Status(Participants) | Personalized Exercise Program | Standard of Care - No Exercise | Total |
|---|---|---|---|
| Urban | 82 | 75 | 157 |
| Rural | 10 | 15 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in May 2022, 54 months.
Results were first posted in Jun 2026, 4 years after primary completion.
Of 109 non-industry phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 129. This study's 54 months is below that.
Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →